Skip to main content
. 2017 Jul 10;8(37):62195–62207. doi: 10.18632/oncotarget.19150

Figure 2. Downregulation of SFRP4 in PDAC and its clinical implications.

Figure 2

(A) The relative expression of SFRP4 mRNA in 36 cases of fresh human PDAC tissues and matched adjacent normal tissues in the same serial section was compared. (B) Western blotting indicated that patients without regional lymph node metastases (LN-) had relatively high expression of SFRP4. (C) The downregulation of SFRP4 was correlated with poor overall survival in patients with resectable PDAC according to univariate analyses.